Ryan Sweeney

@RyanSweeneyMD

UPMC Heme/Onc Fellow | AHN IM '24 | Loyola Stritch '21 | Notre Dame '17 | Views are my own/not medical advice

Beigetreten Ağustos 2025

94 Folgt44 Follower

Ryan Sweeney@RyanSweeneyMD·16 Nis

Honored to serve a program that has done so much for me and to do so alongside the best co-chief 🫡 Looking forward to an exciting academic year!

UPMC Heme-Onc Fellowship Program@UPMCHeme_Onc

🎉 We’re thrilled to announce Dr. Randolph Lyde MD, PhD and Dr. Ryan Sweeney MD as our new Chief Fellows for coming academic year! Your leadership, dedication, and commitment to our program are truly inspiring. Here’s to a bright and exciting year ahead!✨#Congrats #ChiefFellows

English

485

Ryan Sweeney@RyanSweeneyMD·5 Kas

Thank you to @MPishvaian and @TumorBoardTues for the opportunity and of course to my incredible mentor @AnwaarSaeed3 for the privilege to co-present this exciting data! 🙏📈

Mike Pishvaian@MPishvaian

@RyanSweeneyMD @TumorBoardTues @AnwaarSaeed3 @IntegrityCE @myESMO @TheLancet #tumorboardtuesday 🧐I don't know about you all - but I now feel fully prepared and confident in offering a patient zanza + atezo (assuming the combination gets approved) 🙏Thank you @AnwaarSaeed3 and @RyanSweeneyMD. That was a highly instructive session

English

980

Ryan Sweeney@RyanSweeneyMD·5 Kas

@AnwaarSaeed3 @MPishvaian @TumorBoardTues @IntegrityCE @myESMO @TheLancet Excellent question, I think STELLAR-303 opens up many avenues for further research now that there is data for a role of IO in this space!

English

243

Anwaar Saeed@AnwaarSaeed3·5 Kas

@MPishvaian @RyanSweeneyMD @TumorBoardTues @IntegrityCE @myESMO @TheLancet Typically the RAS wildtype patients has more immune permissive TME but there is no data on post IO progression and response to EGFR rechallenge.

English

277

#TumorBoardTuesday@TumorBoardTues·4 Kas

#TumorBoardTuesday 💙Did I hear that there was a ➕ Ph3 trial in met #colorectalcancer ⁉️ 📢Join us Tuesday, 11-04-25 at 8PM ET as @AnwaarSaeed3 & @RyanSweeneyMD🗣️Stellar 303 and the emerging Role for IO regimens in MSS/pMMR CRC✅ RT and bring others into the discussion‼️

English

2.5K

Ryan Sweeney@RyanSweeneyMD·5 Kas

@TumorBoardTues @AnwaarSaeed3 @IntegrityCE @myESMO @TheLancet #PostTest Q2️⃣ #TumorBoardTuesday 👉🏽 Free CME 🔗 integrityce.com/TBT2025 🧐 In the phase 3 STELLAR-303 study of zanzalintinib ➕ atezolizumab versus regorafenib for previously treated mCRC, the combination demonstrated survival benefits in tumors that were:

English

421

Ryan Sweeney@RyanSweeneyMD·5 Kas

@TumorBoardTues @AnwaarSaeed3 @IntegrityCE @myESMO @TheLancet #PostTest Q1️⃣ #TumorBoardTuesday 👉🏽#CME Eval 🔗 integrityce.com/TBTeval25 👉🏽ALL CME🔗 integrityce.com/TBT2025 🤔 Which is NOT true about dMMR/MSI-H CRCs compared with those that are that are pMMR/MSS❓

English

294

Ryan Sweeney@RyanSweeneyMD·5 Kas

@TumorBoardTues @AnwaarSaeed3 @IntegrityCE @myESMO @TheLancet 🔗⬇️ #google_vignette" target="_blank" rel="nofollow noopener">jamanetwork.com/journals/jaman…

QME

181

Entdecken

@MPishvaian @TumorBoardTues @AnwaarSaeed3 @IntegrityCE @myESMO @TheLancet @elonmusk @BarackObama